Memo Therapeutics: Series C financing

Schlieren / Zurich, Switzerland, 7th May, 2024 – Memo Therapeutics AG (or "MTx") today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.

Scenic Biotech: Collaboration BMS

Amsterdam, the Netherlands, April 30, 2024 – Scenic Biotech today announced that it has entered into a research collaboration with Bristol Myers Squibb (NYSE: BMY) to accelerate the development of Bristol Myers Squibb's drug targets by identifying target biology for indication selection and expansion.

Mecuris: Ottobock technology transfer

Munich, February, 29th 2024 – Munich based Mecuris GmbH and Ottobock SE & Co. KGaA agreed on the transfer of technology for the creation of individualized O&P devices. The software developed for the Mecuris Solution Platform enables orthopaedic technicians to design and build customized 3D-printed prosthetic- and orthotic-products.

Rejuvenate: Potential of RJx-01

Diepenbeek, Belgium, February 21st, 2024 – Rejuvenate Biomed NV ("Rejuvenate Biomed"), a pioneering clinical-stage platform and pipeline company committed to enhancing lifelong health through innovative therapeutics, today announces breakthrough functional outcome results from its Phase 1b trial of lead candidate RJx-01 for the treatment of sarcopenia.

Caresyntax: Healthcare‘s Fierce 15

SAN FRANCISCO, February 16, 2024 – Caresyntax, a pioneer in surgical intelligence and automation technologies, is excited to announce its recognition as one of the Fierce Healthcare's Fierce 15 of 2024, a prestigious acknowledgment of the most innovative healthcare companies across the United States.

Memo Therapeutics: Management Team

Schlieren / Zurich, Switzerland, February 5, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company developing best-in-class therapeutic antibodies for viral infections and oncology, announced today that it has strengthened its senior team with the appointments of Kristie B. Clemmer and Dr. Maartje Verschuur as VP Clinical Operations and VP CMC and Supply Chain Management, respectively, effective today.

CatalYm: Positive Phase 2a Outcome

Munich, Germany, December 6, 2023 – CatalYm announced that maturing Phase 2a results from its ongoing GDFATHER-2 trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 2) (NCT04725474) were presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023 in Geneva, Switzerland.

Memo Therapeutics: CEO Erik van den Berg

Schlieren / Zurich, Switzerland – November 16, 2023 – Memo Therapeutics AG ("MTx"), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).

Memo Therapeutics: CHF 25 Million Financing

Schlieren / Zurich, Switzerland – November 2, 2023 – Memo Therapeutics AG ("MTx"), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the closing of a CHF25 million Series C financing led by Pureos Bioventures.

Rejuvenate Biomed: Positive results

Diepenbeek, Belgium, October 4, 2023 – Rejuvenate Biomed NV ("Rejuvenate Biomed"), a clinical-stage company dedicated to advancing therapeutics to delay the onset of age-related diseases, today announced the successful completion of a 6-week clinical proof-of-mechanism study with lead candidate RJx-01. RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects with disuse-induced muscle atrophy.